Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt.
Kharkiv National Medical University, Kharkiv, Ukraine.
Indian Heart J. 2023 Mar-Apr;75(2):98-107. doi: 10.1016/j.ihj.2023.02.001. Epub 2023 Feb 8.
radiofrequency catheter ablation (RFA) is the first-line therapy for symptomatic Wolff Parkinson White (WPW) patients according to the American Heart Association. We conducted this study to assess the success rate, recurrence rate, and rate of complications associated with the utilization of radiofrequency catheter ablation for managing patients with WPW.
We searched PubMed, Cochrane library, Web of Science and Scopus databases using all identified keywords and index terms through 4 January 2022. We included all studies conducted on WPW patients who were treated with ablation. We conducted the analysis using Open Meta Analyst and MedCalc version 19.1.
Among 2268 unique articles identified, only 11 articles met our inclusion criteria. The pooled effect estimates showed high success rate (94.1%[95%CI:92.3-95.9], p < 0.001)), low recurrence rate (6.2% [95%CI:4.5-7.8, p < 0.001]) and low rate of complications (1%[95%CI:0.4-1.5, p < 0.001]).
RFA showed a high success rate, low recurrence rate and low rate of complications in WPW patients.
根据美国心脏协会的建议,射频导管消融(RFA)是治疗有症状的 Wolff Parkinson White(WPW)患者的一线疗法。我们进行这项研究旨在评估射频导管消融治疗 WPW 患者的成功率、复发率和并发症发生率。
我们通过 2022 年 1 月 4 日之前使用所有已确定的关键词和索引词,在 PubMed、Cochrane 图书馆、Web of Science 和 Scopus 数据库中进行了搜索。我们纳入了所有使用消融治疗 WPW 患者的研究。我们使用 Open Meta Analyst 和 MedCalc 版本 19.1 进行了分析。
在 2268 篇独特的文章中,只有 11 篇符合我们的纳入标准。汇总的效应估计显示出高成功率(94.1%[95%CI:92.3-95.9],p<0.001))、低复发率(6.2%[95%CI:4.5-7.8,p<0.001])和低并发症发生率(1%[95%CI:0.4-1.5,p<0.001])。
RFA 显示出 WPW 患者高成功率、低复发率和低并发症发生率。